Opthea Limited (OPT)
|Net Income (ttm)||-11.62M|
|Trading Day||January 25|
|Day's Range||11.91 - 12.35|
|52-Week Range||11.11 - 13.50|
Nine IPOs and five SPACs went public this past week, and one IPO postponed.
MELBOURNE, Australia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT, Nasdaq: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent a...
Opthea, an Australian clinical stage biotech company, is going public to help fund its Phase 3 trials and take on two large biotech companies. About Opthea: The main area of focus for Opthea L...
Opthea has filed proposed terms to raise capital from a U.S. IPO.
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The c... [Read more...]
|IPO Date |
Oct 16, 2020
|Stock Exchange |
|Ticker Symbol |
In 2020, Opthea's revenue was 87,075, a decrease of -45.26% compared to the previous year's 159,064. Losses were -16.53 million, -20.95% less than in 2019.